Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07267065 · ClinicalTrials.gov registry record · Phase 1
AAV2-hAADC for Parkinson's Disease (PDCS-01)
A Phase 1 study, sponsored by Krzysztof Bankiewicz.
- Not yet
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT07267065 is a Phase 1 study that has not yet begun recruiting, run by Krzysztof Bankiewicz. The registered enrollment target is 9 participants.
The verdict
NCT07267065, a Phase 1 study, has not yet begun recruiting, sponsored by Krzysztof Bankiewicz.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study is looking at whether a gene therapy called AAV2-hAADC is safe and may help people with Parkinson's Disease. AAV2-hAADC is intended to increase the levels of dopamine in your brain. It contains a virus called adeno-associated virus 2 (AAV2) that has been modified to carry the genetic code for an enzyme called Aromatic L-Amino Acid Decarboxylase, or AADC for short. In this study, AAV2-hAADC is delivered to two parts of the brain called the putamen and the caudate. Increasing the amount of AADC gene in these parts of the brain converts more levodopa into dopamine, the chemical that is lacking in PD.
Interventions
- DRUG AAV2-hAADC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2026-02-01 |
| Est. Completion | 2028-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07267065
The ClinicalTrials.gov registry entry for NCT07267065 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Krzysztof Bankiewicz, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AAV2-hAADC is the first listed.
NCT07267065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07267065 about?
NCT07267065 is a clinical study titled "AAV2-hAADC for Parkinson's Disease (PDCS-01)". This study is looking at whether a gene therapy called AAV2-hAADC is safe and may help people with Parkinson's Disease. AAV2-hAADC is intended to increase the levels of dopamine in your brain. It contains a virus called adeno-associated virus 2 (AAV2) that has been modified to carry the genetic cod...
What is the current status of trial NCT07267065?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2026-02-01. Estimated completion is 2028-12-01.
What interventions are being tested in trial NCT07267065?
The interventions under investigation include: AAV2-hAADC (DRUG).
Who is sponsoring clinical trial NCT07267065?
This trial is sponsored by Krzysztof Bankiewicz, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.